vs
Side-by-side financial comparison of ASGN Inc (ASGN) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $970.0M, roughly 1.1× ASGN Inc). ASGN Inc runs the higher net margin — 0.6% vs -127.8%, a 128.4% gap on every dollar of revenue. On growth, PERRIGO Co plc posted the faster year-over-year revenue change (-2.5% vs -3.0%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $9.1M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -3.2%).
ASGN Inc is a leading U.S.-headquartered professional services and workforce solutions provider. It specializes in supplying skilled talent and consulting services across high-growth segments including information technology, creative, digital, life sciences, and engineering, primarily serving enterprise clients across North America.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ASGN vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $970.0M | $1.1B |
| Net Profit | $5.5M | $-1.4B |
| Gross Margin | 27.5% | 32.6% |
| Operating Margin | 2.9% | -116.0% |
| Net Margin | 0.6% | -127.8% |
| Revenue YoY | -3.0% | -2.5% |
| Net Profit YoY | -73.7% | -3093.9% |
| EPS (diluted) | $0.13 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $970.0M | — | ||
| Q4 25 | $980.1M | $1.1B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $968.3M | $1.0B | ||
| Q4 24 | $985.0M | $1.1B | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $1.0B | $1.1B |
| Q1 26 | $5.5M | — | ||
| Q4 25 | $25.2M | $-1.4B | ||
| Q3 25 | $38.1M | $7.5M | ||
| Q2 25 | $29.3M | $-8.4M | ||
| Q1 25 | $20.9M | $-6.4M | ||
| Q4 24 | $42.4M | $-44.4M | ||
| Q3 24 | $47.5M | $-21.0M | ||
| Q2 24 | $47.2M | $-108.4M |
| Q1 26 | 27.5% | — | ||
| Q4 25 | 28.9% | 32.6% | ||
| Q3 25 | 29.4% | 36.1% | ||
| Q2 25 | 28.7% | 34.4% | ||
| Q1 25 | 28.4% | 37.6% | ||
| Q4 24 | 29.0% | 33.9% | ||
| Q3 24 | 29.1% | 37.2% | ||
| Q2 24 | 29.1% | 37.0% |
| Q1 26 | 2.9% | — | ||
| Q4 25 | 5.7% | -116.0% | ||
| Q3 25 | 6.7% | 7.0% | ||
| Q2 25 | 5.8% | 4.3% | ||
| Q1 25 | 4.8% | 4.5% | ||
| Q4 24 | 7.5% | 10.0% | ||
| Q3 24 | 7.7% | 7.4% | ||
| Q2 24 | 7.8% | -2.5% |
| Q1 26 | 0.6% | — | ||
| Q4 25 | 2.6% | -127.8% | ||
| Q3 25 | 3.8% | 0.7% | ||
| Q2 25 | 2.9% | -0.8% | ||
| Q1 25 | 2.2% | -0.6% | ||
| Q4 24 | 4.3% | -3.9% | ||
| Q3 24 | 4.6% | -1.9% | ||
| Q2 24 | 4.6% | -10.2% |
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.58 | $-10.23 | ||
| Q3 25 | $0.87 | $0.05 | ||
| Q2 25 | $0.67 | $-0.06 | ||
| Q1 25 | $0.48 | $-0.05 | ||
| Q4 24 | $0.94 | $-0.32 | ||
| Q3 24 | $1.06 | $-0.15 | ||
| Q2 24 | $1.02 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $143.6M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $1.8B | $2.9B |
| Total Assets | $4.0B | $8.5B |
| Debt / EquityLower = less leverage | 0.82× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $143.6M | — | ||
| Q4 25 | $161.2M | — | ||
| Q3 25 | — | $432.1M | ||
| Q2 25 | — | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | $205.2M | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $2.9B | ||
| Q3 25 | $1.8B | $4.4B | ||
| Q2 25 | $1.8B | $4.5B | ||
| Q1 25 | $1.8B | $4.4B | ||
| Q4 24 | $1.8B | $4.3B | ||
| Q3 24 | $1.8B | $4.6B | ||
| Q2 24 | $1.8B | $4.5B |
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $8.5B | ||
| Q3 25 | $3.7B | $10.1B | ||
| Q2 25 | $3.7B | $10.1B | ||
| Q1 25 | $3.7B | $9.8B | ||
| Q4 24 | $3.4B | $9.6B | ||
| Q3 24 | $3.4B | $11.2B | ||
| Q2 24 | $3.5B | $10.4B |
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.65× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.57× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | $9.1M | $148.6M |
| FCF MarginFCF / Revenue | 0.9% | 13.4% |
| Capex IntensityCapex / Revenue | 1.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $290.6M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $102.3M | $175.4M | ||
| Q3 25 | $83.9M | $51.7M | ||
| Q2 25 | $124.9M | $75.9M | ||
| Q1 25 | $16.8M | $-64.5M | ||
| Q4 24 | $100.2M | $312.6M | ||
| Q3 24 | $135.8M | $42.2M | ||
| Q2 24 | $90.7M | $9.5M |
| Q1 26 | $9.1M | — | ||
| Q4 25 | $93.7M | $148.6M | ||
| Q3 25 | $72.0M | $29.8M | ||
| Q2 25 | $115.8M | $56.7M | ||
| Q1 25 | $6.6M | $-90.0M | ||
| Q4 24 | $88.9M | $274.9M | ||
| Q3 24 | $127.9M | $15.1M | ||
| Q2 24 | $85.4M | $-18.9M |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.6% | 13.4% | ||
| Q3 25 | 7.1% | 2.9% | ||
| Q2 25 | 11.3% | 5.4% | ||
| Q1 25 | 0.7% | -8.6% | ||
| Q4 24 | 9.0% | 24.2% | ||
| Q3 24 | 12.4% | 1.4% | ||
| Q2 24 | 8.3% | -1.8% |
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 2.4% | ||
| Q3 25 | 1.2% | 2.1% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 1.1% | 3.3% | ||
| Q3 24 | 0.8% | 2.5% | ||
| Q2 24 | 0.5% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 2.20× | 6.89× | ||
| Q2 25 | 4.26× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 2.36× | — | ||
| Q3 24 | 2.86× | — | ||
| Q2 24 | 1.92× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASGN
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
